216 related articles for article (PubMed ID: 9723363)
21. Case study: de novo application of Neoral in renal transplantation.
Kahan BD
Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
[No Abstract] [Full Text] [Related]
22. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.
Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M
Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994
[No Abstract] [Full Text] [Related]
23. Time-dependent difference of the 12-hour trough levels of cyclosporine in renal transplant recipients with sandimmune capsule.
To H; Haba T; Uchida K; Fujimura A; Kobayashi E
Transplant Proc; 2000 Feb; 32(1):221-2. PubMed ID: 10701028
[No Abstract] [Full Text] [Related]
24. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
[No Abstract] [Full Text] [Related]
25. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral.
Melter M; Rodeck B; Kardorff R; Hoyer PF; Brodehl J
Transpl Int; 1997; 10(6):419-25. PubMed ID: 9428114
[TBL] [Abstract][Full Text] [Related]
26. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
Konstadinidou I; Boletis JN
Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
[TBL] [Abstract][Full Text] [Related]
27. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants.
Foradori A; Mezzano S; Videla C; Pefaur J; Elberg A
Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244
[No Abstract] [Full Text] [Related]
28. Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation.
Meier-Kriesche HU; Swinford R; Kahan BD; Brannan P; Portman RJ
Pediatr Nephrol; 2000 Nov; 15(1-2):2-6. PubMed ID: 11095000
[TBL] [Abstract][Full Text] [Related]
29. Conventional versus Neoral cyclosporine in renal transplantation.
Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
[No Abstract] [Full Text] [Related]
30. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
31. Cyclosporine peak concentration in relation to the four-hour absorption phase in pediatric renal graft recipients.
Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
Transplant Proc; 2001; 33(7-8):3126-7. PubMed ID: 11750344
[No Abstract] [Full Text] [Related]
32. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
[No Abstract] [Full Text] [Related]
33. Neoral versus Sandimmun in kidney-pancreas transplantation.
Rigotti P; Cadrobbi R; Baldan N; Ferraresso M; Di Landro D; Marchini F; Zaninotto G; Palatini P
Transplant Proc; 1997 Nov; 29(7):2924-6. PubMed ID: 9365616
[No Abstract] [Full Text] [Related]
34. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
[No Abstract] [Full Text] [Related]
35. The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Toze CL; Corr T; Currie C; Strong DK; Keown PA
Transplant Proc; 1998 Aug; 30(5):1668-70. PubMed ID: 9723236
[No Abstract] [Full Text] [Related]
36. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
Lee KL; Lee KT; Chung HM; Lin YP
Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
[No Abstract] [Full Text] [Related]
37. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group.
Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ
Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231
[No Abstract] [Full Text] [Related]
38. Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients.
Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
Transplant Proc; 2003 Jun; 35(4):1300-3. PubMed ID: 12826143
[TBL] [Abstract][Full Text] [Related]
39. Study of neoral kinetics in adult renal transplantation treated with diltiazem.
Mezzano S; Flores C; Ardiles L; Foradori A; Elberg A
Transplant Proc; 1998 Aug; 30(5):1660-2. PubMed ID: 9723232
[No Abstract] [Full Text] [Related]
40. Mass conversion from Sandimmun to Sandimmun Neoral: 1 1/2-year experience.
Huraib S; al Khudair W; Selim H; Iqbal A; Quadri K; Abu Romeh S; Chaballout A
Transplant Proc; 1997 Nov; 29(7):2980-2. PubMed ID: 9365637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
